MALVERN, Pa., Jan. 31, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical ...
The financial landscape of United States professional sports is rapidly evolving. Soaring team valuations, lucrative media rights deals, ...
SAN FRANCISCO - 89bio, Inc. (NASDAQ:ETNB), a biopharmaceutical company specializing in liver and cardiometabolic diseases with a current market capitalization of $1.05 billion, has initiated a public ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback